ORGANOGENESIS HOLDINGS INC. Research and Development Expense
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Research and Development Expense of $18.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- ORGANOGENESIS HOLDINGS INC. research and development expense for the quarter ending 2026-06-30 was $18.30M, a 76.02% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. research and development expense for the quarter ending 2026-03-31 was $15.16M, a 42.49% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. research and development expense for the quarter ending 2025-12-31 was $10.29M, a 10.79% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. research and development expense for the quarter ending 2025-09-30 was $13.22M, a 27.81% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. research and development expense for fiscal 2025 was $44.54M, a 11.40% decline from fiscal 2024.
- ORGANOGENESIS HOLDINGS INC. research and development expense for fiscal 2024 was $50.27M, a 13.27% increase from fiscal 2023.
- ORGANOGENESIS HOLDINGS INC. research and development expense for fiscal 2023 was $44.38M, a 11.61% increase from fiscal 2022.
- ORGANOGENESIS HOLDINGS INC. research and development expense for fiscal 2022 was $39.76M, a 29.34% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.30M 10-Q · filed 2026-08-06 | $33.46M 10-Q · filed 2026-08-06 | $43.74M derived: sum of 3 quarters · filed 2026-08-06 | $56.97M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $15.16M 10-Q · filed 2026-05-07 | $25.45M derived: sum of 2 quarters · filed 2026-05-07 | $38.67M derived: sum of 3 quarters · filed 2026-05-07 | $49.06M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $10.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $23.51M derived: sum of 2 quarters · filed 2026-02-26 | $33.90M derived: sum of 3 quarters · filed 2026-08-06 | $44.54M 10-K · filed 2026-02-26 |
| 2025-09-30 | $13.22M 10-Q · filed 2025-11-06 | $23.62M derived: sum of 2 quarters · filed 2026-08-06 | $34.26M 10-Q · filed 2025-11-06 | $45.79M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $10.39M 10-Q · filed 2026-08-06 | $21.04M 10-Q · filed 2026-08-06 | $32.56M derived: sum of 3 quarters · filed 2026-08-06 | $42.91M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $10.64M 10-Q · filed 2026-05-07 | $22.17M derived: sum of 2 quarters · filed 2026-05-07 | $32.51M derived: sum of 3 quarters · filed 2026-05-07 | $48.10M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $11.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $21.87M derived: sum of 2 quarters · filed 2026-02-26 | $37.46M derived: sum of 3 quarters · filed 2026-02-26 | $50.27M 10-K · filed 2026-02-26 |
| 2024-09-30 | $10.34M 10-Q · filed 2025-11-06 | $25.93M derived: sum of 2 quarters · filed 2025-11-06 | $38.74M 10-Q · filed 2025-11-06 | $50.51M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $15.59M 10-Q · filed 2025-08-07 | $28.40M 10-Q · filed 2025-08-07 | $40.17M derived: sum of 3 quarters · filed 2026-02-26 | $50.64M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $12.81M 10-Q · filed 2025-05-08 | $24.58M derived: sum of 2 quarters · filed 2026-02-26 | $35.05M derived: sum of 3 quarters · filed 2026-02-26 | $45.99M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $11.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $22.24M derived: sum of 2 quarters · filed 2026-02-26 | $33.18M derived: sum of 3 quarters · filed 2026-02-26 | $44.38M 10-K · filed 2026-02-26 |
| 2023-09-30 | $10.47M 10-Q · filed 2024-11-12 | $21.41M derived: sum of 2 quarters · filed 2024-11-12 | $32.61M 10-Q · filed 2024-11-12 | $44.01M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $10.94M 10-Q · filed 2024-08-08 | $22.14M 10-Q · filed 2024-08-08 | $33.53M derived: sum of 3 quarters · filed 2025-02-27 | $43.11M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $11.20M 10-Q · filed 2024-05-09 | $22.60M derived: sum of 2 quarters · filed 2025-02-27 | $32.17M derived: sum of 3 quarters · filed 2025-02-27 | $42.38M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $11.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $20.97M derived: sum of 2 quarters · filed 2025-02-27 | $31.18M derived: sum of 3 quarters · filed 2025-02-27 | $39.76M 10-K · filed 2025-02-27 |
| 2022-09-30 | $9.57M 10-Q · filed 2023-11-09 | $19.78M derived: sum of 2 quarters · filed 2023-11-09 | $28.37M 10-Q · filed 2023-11-09 | $36.63M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $10.21M 10-Q · filed 2023-08-09 | $18.79M 10-Q · filed 2023-08-09 | $27.05M derived: sum of 3 quarters · filed 2024-02-29 | $36.01M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $8.59M 10-Q · filed 2023-05-10 | $16.85M derived: sum of 2 quarters · filed 2024-02-29 | $25.80M derived: sum of 3 quarters · filed 2024-02-29 | $33.12M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $8.26M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $17.21M derived: sum of 2 quarters · filed 2024-02-29 | $24.53M derived: sum of 3 quarters · filed 2024-02-29 | $30.74M 10-K · filed 2024-02-29 |
| 2021-09-30 | $8.95M 10-Q · filed 2022-11-09 | $16.27M derived: sum of 2 quarters · filed 2022-11-09 | $22.48M 10-Q · filed 2022-11-09 | $28.78M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $7.32M 10-Q · filed 2022-08-09 | $13.53M 10-Q · filed 2022-08-09 | $19.83M derived: sum of 3 quarters · filed 2023-03-01 | $23.54M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $6.21M 10-Q · filed 2022-05-10 | $12.51M derived: sum of 2 quarters · filed 2023-03-01 | $16.22M derived: sum of 3 quarters · filed 2023-03-01 | $20.89M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $6.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $10.01M derived: sum of 2 quarters · filed 2023-03-01 | $14.68M derived: sum of 3 quarters · filed 2023-03-01 | $20.09M 10-K · filed 2023-03-01 |
| 2020-09-30 | $3.71M 10-Q · filed 2021-11-09 | $8.38M derived: sum of 2 quarters · filed 2021-11-09 | $13.79M 10-Q · filed 2021-11-09 | $17.43M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $4.67M 10-Q · filed 2021-08-09 | $10.08M 10-Q · filed 2021-08-09 | $13.72M derived: sum of 3 quarters · filed 2022-03-01 | $17.64M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $5.41M 10-Q · filed 2021-05-11 | $9.05M derived: sum of 2 quarters · filed 2022-03-01 | $12.97M derived: sum of 3 quarters · filed 2022-03-01 | $16.84M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $3.64M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $7.56M derived: sum of 2 quarters · filed 2022-03-01 | $11.43M derived: sum of 3 quarters · filed 2022-03-01 | $14.80M 10-K · filed 2022-03-01 |
| 2019-09-30 | $3.92M 10-Q · filed 2020-11-09 | $7.79M derived: sum of 2 quarters · filed 2020-11-09 | $11.16M 10-Q · filed 2020-11-09 | $14.25M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $3.86M 10-Q · filed 2020-08-10 | $7.24M 10-Q · filed 2020-08-10 | $10.33M derived: sum of 3 quarters · filed 2020-08-10 | $13.11M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $3.37M 10-Q · filed 2020-05-11 | $6.46M derived: sum of 2 quarters · filed 2020-05-11 | $9.24M derived: sum of 3 quarters · filed 2020-05-11 | $11.29M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $3.09M 10-K · filed 2019-03-18 | $5.87M derived: sum of 2 quarters · filed 2019-11-12 | $7.92M derived: sum of 3 quarters · filed 2019-11-12 | $10.74M 10-K · filed 2021-03-16 |
| 2018-09-30 | $2.78M 10-Q · filed 2019-11-12 | $4.83M derived: sum of 2 quarters · filed 2019-11-12 | $7.65M 10-Q · filed 2019-11-12 | $10.39M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $2.05M 10-Q · filed 2019-08-09 | $4.87M 10-Q · filed 2019-08-09 | $7.61M derived: sum of 3 quarters · filed 2019-08-09 | $9.93M derived: sum of 4 quarters · filed 2019-08-09 |
| 2018-03-31 | $2.82M 10-Q · filed 2019-05-10 | $5.56M derived: sum of 2 quarters · filed 2019-05-10 | $7.88M derived: sum of 3 quarters · filed 2019-05-10 | $10.34M derived: sum of 4 quarters · filed 2019-05-10 |
| 2017-12-31 | $2.73M 10-K · filed 2019-03-18 | $5.06M derived: sum of 2 quarters · filed 2019-03-18 | $7.51M derived: sum of 3 quarters · filed 2019-03-18 | $9.06M 10-K · filed 2020-03-09 |
| 2017-09-30 | $2.33M 10-K · filed 2019-03-18 | $4.78M derived: sum of 2 quarters · filed 2019-03-18 | $6.33M derived: sum of 3 quarters · filed 2019-03-18 | |
| 2017-06-30 | $2.45M 10-K · filed 2019-03-18 | $4.00M derived: sum of 2 quarters · filed 2019-03-18 | ||
| 2017-03-31 | $1.55M 10-K · filed 2019-03-18 | |||
| 2016-12-31 | $6.28M 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |